The life sciences logistics firm reports Q2 2026 revenue of $49 million and maintains full-year guidance amid adjusted EBITDA growth.
Cryoport Inc. (CYRX) confirmed its 2026 revenue guidance of $192M to $196M, citing sustained momentum in its life sciences business. The company reported $49 million in revenue for Q2 2026, aligning with its growth trajectory.
Management attributed the performance to strong demand in the life sciences sector, though prior quarter comparisons or consensus estimates were not disclosed. The firm also reiterated its focus on expanding adjusted EBITDA.
No immediate market reaction was detailed in the earnings call summary.